Loading
Epigenetics and DNA Methylation / Ferroptosis and Cancer Prognosis · Journal article
International Dental Journal · September 10, 2026
Raises a question worth testing. It does not answer one.
This scoping review documents strong preclinical evidence that Sp1, a transcription factor, drives multiple oncogenic programs in OSCC including EMT, chemoresistance, and immune evasion, and that multiple agents suppress Sp1 in xenograft models. However, no Sp1-directed therapy has entered clinical testing, and human tissue evidence is sparse, indicating a translational gap rather than established clinical utility.
Scoping review with secondary scRNA-seq analysis. Original studies of Sp1 in OSCC or tongue SCC; scRNA-seq analysis included tumor cells from patient samples.. Intervention: Sp1 expression, regulation, downstream targets, and therapeutic interventions (natural and synthetic agents suppressing Sp1)..
Sp1 overexpression associated with advanced clinical stage, metastasis, and poor prognosis across thirty-eight studies, though human-tissue evidence limited to two studies Sp1 transcriptionally activated genes linked to EMT, survival, oncogenic signaling, and immune evasion in OSCC models Multiple natural and synthetic agents suppressed Sp1 and induced apoptosis, with xenograft validation in several reports
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Despite preclinical evidence of Sp1's role in OSCC oncogenesis and druggability, clinicians should note that no Sp1-targeted therapy has been tested in humans, and the sparse human-tissue evidence (two studies) does not yet support clinical decision-making. This work identifies Sp1 as a translational research priority rather than an actionable therapeutic target.
A scoping review synthesizing preclinical and mechanistic evidence on Sp1 in OSCC with scRNA-seq analysis, raising translational questions but reporting no clinical trials or human efficacy data.
As stated by the source record.
Quoted from the source exactly as published.
Despite preclinical evidence of Sp1's role in OSCC oncogenesis and druggability, clinicians should note that no Sp1-targeted therapy has been tested in humans, and the sparse human-tissue evidence (two studies) does not yet support clinical decision-making. This work identifies Sp1 as a translational research priority rather than an actionable therapeutic target.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Oral squamous cell carcinoma (OSCC) remains the most common oral malignancy and has limited targeted therapeutic options. Specificity protein 1 (Sp1), a versatile zinc-finger transcription factor, has emerged as a pivotal regulator of cellular proliferation, apoptosis, epithelial–mesenchymal transition (EMT), and chemoresistance. However, OSCC-specific evidence has not been systematically integrated. This study synthesizes current evidence on Sp1 expression, regulation, downstream targets, and therapeutic interventions in OSCC to map the landscape and identify priorities for translational research. Following PRISMA-ScR guidelines, PubMed, Embase, Scopus, and Web of Science (2002-2025) were searched for original studies of Sp1 in OSCC/tongue SCC. Data on regulatory mechanisms, downstream targets, phenotypic effects, and therapeutic interventions were extracted. Public scRNA-seq data (GSE103322; 5,865 cells from 18 tumors) were analyzed using patient-aware, cell type-stratified Spearman correlation and gene set enrichment analysis to characterize Sp1-associated transcriptional covariation across tumor compartments. Across thirty-eight studies, Sp1 overexpression was reported in association with advanced clinical stage, metastasis, and poor prognosis, though human-tissue evidence was limited to two studies. Upstream regulations involved tumor-suppressive microRNAs, oncogenic non-coding RNAs, and post-translational modifications. Sp1 transcriptionally activated genes linked to EMT, survival, oncogenic signaling, and immune evasion. Multiple natural and synthetic agents suppressed Sp1 and induced apoptosis, with xenograft validation in several reports. Sp1 is reported to regulate multiple oncogenic programs in OSCC, predominantly in preclinical models. Despite strong preclinical evidence, no Sp1-directed therapy has entered clinical testing, underscoring a critical translational gap and the need for biomarker-driven combination strategies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.